



A Rare Case of Methotrexate Induced Pancreatitis in Ectopic Pregnancy

Jiwon Choi¹, Mina Kang¹, Young Min Hur¹, Young Ju Kim¹, Sunwha Park¹

Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Seoul, Korea

Received Jan 19, 2023
Revised Mar 14, 2023
Accepted Apr 5, 2023

Corresponding author

Sunwha Park
Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea
Tel: 82-2-2650-5015
E-mail: clarrissa15@gmail.com

Key Words

Pregnancy, ectopic; Methotrexate; Pancreatitis

Ectopic pregnancy (EP) refers to blastocyst implantation outside the uterine endometrium. EP is major cause of maternal morbidity and mortality. Treatment options include surgery, medical therapy with methotrexate, or expectant management. Methotrexate is the primary regimen used in cases of early, unruptured ectopic pregnancies. Most side effects of methotrexate are minor, including nausea, vomiting, abdominal discomfort, and photosensitive skin reaction. Serious side effects, including bone marrow suppression, and pulmonary fibrosis, are invariably observed when methotrexate is administered in high doses with frequent dosing intervals, in chemotherapeutic protocols for malignancy. These side effects are uncommon with the doses used to treat ectopic pregnancies. Since cases of methotrexate-induced pancreatitis are rare, we report a case of pancreatitis in a patient with EP treated with methotrexate and expect to consider pancreatitis as a side effect of methotrexate in a patient with upper abdominal pain undergoing methotrexate chemotherapy.

Introduction

Ectopic pregnancy (EP) refers to blastocyst implantation outside the uterine cavity. The incidence of EP is rising, which can be explained by the increased use of assisted reproductive technologies, tubal surgeries, and improved diagnostic tools [1]. EP is medically important because it is associated with reduced fertility and an increased risk of subsequent EPs [2]. Treatment options for EP involve surgical and medical intervention [1]. Medical treatment primarily uses a regimen of methotrexate (MTX) in cases of early, unruptured EP, and is reported to be safe and effective [1].

MTX is a folic acid analog that competitively binds to dihydrofolic acid reductase, an enzyme that converts dihydrofolate to tetrahydrofolate. This binding prevents the reduction of folate to its active form, tetrahydrofolate. It transports one carbon group during the synthesis of purine nucleotides and thymidylates. MTX impairs DNA synthesis, DNA repair, and cellular replication [3]. MTX selectively acts on rapidly dividing cells, such as trophoblast cells, which comprise the implantation site during early gestation [4]. MTX enters the liver via the hepatic artery and is rapidly cleared from the body by the kidneys, with 90% of the intravenous dose excreted unchanged within 24 h of injection [5,6].

Two common regimens are available for MTX: multidose [MTX 1.0 mg/kg intramuscularly (i.m.) daily; days 0, 2, 4, and 6 alternated with folinic acid 0.1 mg/kg orally on days 1, 3, 5, and 7]; and single dose (MTX 0.4 to 1.0 mg/kg or 50 mg/m² i.m. without folinic acid) [7]. Current regimens of

MTX for the treatment of EP reduce the total MTX dose that patients receive compared to other indications such as chemotherapy. Therefore, the incidence of therapy-related side effects was low [8]. Most side effects of MTX are minor, such as nausea, vomiting, stomatitis, and diarrhea, and have rarely been reported to be linked to pancreatitis.

Acute pancreatitis (AP) is a common disease that affects the digestive system. AP is diagnosed on the basis on the fulfillment of 2 out of 3 of the following criteria : clinical (upper abdominal pain), laboratory (serum amylase or lipase $>3\times$ upper limit of normal) and/or imaging (CT, MRI, ultrasonography) criteria [9]. Various etiologies of AP, most of which are due to gallstones. Other common causes of pancreatitis are alcohol consumption, hyperlipidemia, hypercalcemia, sphincter of Oddi dysfunction, drugs and toxins, which may also be idiopathic or traumatic [10]. The management of AP involves providing active treatment, including fluid resuscitation, nutritional support, analgesics, and etiological treatment [11]. At present, three cases of MTX-induced pancreatitis have been reported [12,13]. We report a case of a 40-year-old woman who underwent MTX therapy for an unruptured EP and developed AP.

Case

A 40-year-old gravida 2, para 1 woman visited the emergency department with upper abdominal pain. She had nausea and a low-grade fever, with a maximum temperature of 37.8°C. Abdominal examination revealed severe tenderness in the epigastric area, and both the right and left upper quadrants without muscle guarding or rebound tenderness.

The patient did not consume any other medications or alcohol. She had visited another hospital four weeks ago because of lower abdominal pain and was diagnosed with a left tubal EP. On that day, her total serum hCG level was 23,544 mIU/mL. She had been treated with a single dose of MTX (99.1 mg), intramuscularly four weeks before her visit to this hospital. A week after MTX injection, her total serum hCG level was 13,166 mIU/mL, and 4,620 mIU/mL after two weeks. Three weeks after the injection the total serum hCG level was 1,400 mIU/mL, and transvaginal sonography revealed a decrease in the size of the left adnexal mass.

Abdominal and pelvic computed tomography scan showed diffuse acute interstitial edematous pancreatitis with peripancreatic fluid collection and infiltration (Fig. 1A) and acute hematoma in the cul-de-sac without active bleeding (Fig. 1C). Upper abdominal ultrasonography findings were consistent with that of AP (Fig. 2A, 2B).

Transvaginal ultrasonography revealed an empty uterus with 2.53 mm thick endometrium



Fig. 1. Abdominal pelvic CT scan on admission day. (A) Pancreatic parenchyma enhancement by intravenous contrast agent. Acute inflammation of the pancreatic parenchyma and peripancreatic tissue, with stranding of the surrounding fat. (B) Acute peripancreatic fluid collection in the left anterior pararenal space. (C) Acute hematoma (arrow) in the cul-de-sac without active bleeding.




Fig. 2. Abdominal sonogram on admission day. (A) Enlarged and swollen of acute pancreatitis (circle) with peripancreatic fluid collection. (B) 1.4 cm anechoic lesion (arrow) around the pancreatic tail, with probable loculated peripancreatic fluid collection.

and a probable ectopic mass at the left adnexa, measuring 3.15 cm in the largest diameter, with degenerated gestational sac inside, but no fetal pole (Fig. 3A). A hematoma sized 7.9×3.5 cm² was noted in the posterior cul-de-sac (Fig. 3B).

According to the laboratory investigations, hemoglobin was 12.6 g/dL (reference range, 12.0–16.0 g/dL), WBC was 8,400 μ L (4,000–10,000 μ L), platelet counts were 349,000 μ L (150,000–450,000 μ L), total bilirubin was 0.38 mg/dL (\leq 1.2 mg/dL) with direct bilirubin level of 0.14 mg/dL (\leq 0.25 mg/dL), AST was 15 IU/L (\leq 33 IU/L), ALT was 8 IU/L (\leq 33 IU/L), ALP was 87 IU/L (30–120 IU/L), total cholesterol was 193 mg/dL (\leq 200 mg/dL), which were within the normal range. The enzymes showed elevated levels: LDH 282 IU/L (135–214 IU/L), amylase 1,864 IU/L (28–100 IU/L), lipase 4,394 IU/L (13–60 IU/L), CRP 0.97 mg/dL (\leq 0.5 mg/dL), triglyceride 178 mg/dL (28–150 mg/dL), fibrinogen 458.1 mg/dL (180–350 mg/dL), FDP 13.7 μ g/mL (\leq 5 μ g/mL), D-dimer 5.44 mg/L (\leq 0.59 mg/L). HCG was detected on urine examination, and the total hCG level on admission was 1,289.0 mIU/mL. Considering her clinical manifestations, laboratory tests, CT scan and abdominal ultrasound findings, the diagnosis of AP was confirmed.

The patient was admitted to the hospital and received conservative medical management with analgesia, hydration and fasting. She received gabexate 20 mg intravenously daily for five days and 100,000 units injection units of ulinastatin intravenously per daily for two days. Those




Fig. 3. Transvaginal sonogram on admission. (A) Coronal view of the left adnexa. The thick-walled left adnexa cystic structure, separate from the ovary, called 'tubal ring sign', which show unruptured tubal ectopic pregnancy. (B) Hematoma, sized 7.9×3.5 cm², in posterior cul-de-sac.

gabexate mesylate and ulinastatin are protease inhibitors, which are accepted as a potential treatment to inhibit the pancreatic inflammation in AP [14].

She was administered ciprofloxacin 400 mg every 12 h intravenously for five days during her hospitalization.

On fourth day after hospitalization, repeated measurements of her amylase and lipase levels were within normal limits: amylase 75 IU/L (28–100 IU/L), lipase 35 U/L (13–60 IU/L); and the total hCG level decreased to 762.0 mIU/mL. The patient's symptoms continued to improve during her course of hospitalization. The patient was discharged with oral ciprofloxacin 500 mg per 12 h for discharge medication, on the 6th day of admission after significant clinical and laboratory improvement. The patient presented with complete resolution of symptoms and biochemical results during ambulatory follow-up. The follow-up transvaginal sonography revealed a decrease in the size of the hematoma and left adnexa mass (Fig. 4A, 4B).

Discussion

We report a rare case of MTX-induced pancreatitis in a patient with EP and treated with MTX. EP may be life threatening, and further treatment is determined based on the patient's hemodynamic status, size of the ectopic mass, and level of beta-hCG. Medical treatment primarily uses the regimen of MTX [1]. Current regimens of MTX reduce the total MTX dose that patients receive compared with other indications such as chemotherapy [4]. Therefore, the incidence of therapy-related side effects is low, and most are minor side effects such as nausea, vomiting, stomatitis, and diarrhea [1]. Cases of MTX-induced pancreatitis are rare, and previous studies have reported a case of a 16-year-old girl with systemic lupus erythematosus acute necrotizing pancreatitis was attributed to a combination regimen involving MTX [12]. Another case report is of a 36-year-old woman who received MTX along with etoposide, actinomycin D, cyclophosphamide, and vincristine for suspected hydatidiform mole developed AP. Moreover, another case of a 10-year-old girl with acute lymphatic leukemia who was treated with vincristine, daunorubicin, L-asparaginase, intrathecal MTX, cyclophosphamide, and oral 6 MP and had MTX-induced pancreatitis has been reported [13]. However, AP after using MTX for the treatment of EP was not found in previously published studies and this report has very important implication that we should consider other differential diagnosis when we evaluate the




Fig. 4. Follow-up transvaginal sonogram after treatment. (A) Complex echoic, irregular shaped left adnexa mass, sized 3.2×2.7 cm². Previously tubal ring sign disappeared and the total size of the mass was decreased. (B) A 5.0×3.1 cm² hematoma in the posterior cul-de-sac.

patient suffering severe abdominal pain, treated with MTX due to EP. Cramp abdominal pain which is self-limiting and controlled with nonsteroidal anti-inflammatory agent is common side effect during MTX for an EP [15]. Also, If a patient with EP experiences severe abdominal pain after MTX therapy, clinicians would mostly suspect ectopic mass rupture, which will necessitate surgical treatment, and other differential diagnosis may be overlooked. However, if there is no evidence of an ectopic mass rupture, suspicion of other causes, laboratory tests, and imaging must be performed based on the clinical manifestations.

The side effects of MTX may be overlooked in the clinical settings of EP. If a patient with EP experiences abdominal pain after MTX therapy, clinicians would mostly suspect ectopic mass rupture, which will necessitate surgical treatment. However, if there is no evidence of an ectopic mass rupture, suspicion of other causes, laboratory tests, and imaging must be performed based on the clinical manifestations.

This case report has some limitations. For the diagnosis of an adverse drug reaction, the time relationship between the use of the drug and the occurrence of the reaction should be assessed. In addition, drug rechallenge should be considered [16]. However, since the patient received a single dose of MTX, there was no chance of rechallenge with drug.

Second, MTX has rarely been reported to be associated with the pancreatitis, and its possible etiology is unknown. Therefore, future studies and case reports are required in this area.

Although MTX-induced pancreatitis is a rare complication, it is important for clinicians to be aware of all possible complications of MTX because it is a widely used medical treatment for EP. We hope that this may aid in the evaluation of patients with severe abdominal pain after using MTX therapy.

Acknowledgments

Not applicable.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

ORCID iD

Jiwon Choi: <https://orcid.org/0000-0003-1724-5269>

Mina Kang: <https://orcid.org/0000-0002-1332-6216>

Young Min Hur: <https://orcid.org/0000-0001-6541-8385>

Young Ju Kim: <https://orcid.org/0000-0002-3153-3008>

Sunwha Park: <https://orcid.org/0000-0001-8142-7783>

Author Contribution

Conceptualization: Kim YJ, Park S

Formal Analysis: Choi J, Kang M, Park S

Investigation: Choi J, Kang M

Methodology: Choi J, Kang M, Park S

Project Administration: Choi J, Kang M

Writing – Original Draft: Choi J, Kang M

Writing – Review & Editing: Choi J, Kang M, Hur YM, Kim YJ, Park S

Ethics Approval and Consent to Participate

Informed consent for publication of the images was obtained from the patient.

References

1. Taran FA, Kagan KO, Hübner M, Hoopmann M, Wallwiener D, Bruker S. The diagnosis and treatment of ectopic pregnancy. *Dtsch Arztebl Int* 2015;112(41):693-703.

2. Chow WH, Daling JR, Cates W JR, Greenberg RS. Epidemiology of ectopic pregnancy. *Epidemiol Rev* 1987;9(1):70-94.
3. Lipscomb GH. Medical management of ectopic pregnancy. *Clin Obstet Gynecol* 2012;55(2):424-432.
4. Barnhart K, Coutifaris C, Esposito M. The pharmacology of methotrexate. *Expert Opin Pharmacother* 2005;2(3):409-417.
5. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. *Cancer* 1978;41(1):36-51.
6. Kremer JM. Toward a better understanding of methotrexate. *Arthrit Rheumat* 2004;50(5):1370-1382.
7. Condous G, Okaro E, Khalid A, Lu C, Van Huffel S, Timmerman D, et al. A prospective evaluation of a single-visit strategy to manage pregnancies of unknown location. *Hum Reprod* 2005;20(5):1398-1403.
8. Stovall TG, Ling FW, Gray LA, Carson SA, Buster JE. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. *Obstet Gynecol* 1991;77(5):749-753.
9. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology* 2013;13(4):Se1-Se15.
10. Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeny P, et al. Guidelines for the management of acute pancreatitis. *J Gastroenterol Hepatol* 2002;17:S15-S39.
11. Zheng Z, Ding YX, Qu YX, Cao F, Li F. A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management. *Ann Transl Med* 2021;9(1):69.
12. Kolk A, Horneff G, Wilgenbus KK, Wahn V, Gerharz CD. Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus--possible toxicity of immunosuppressive therapy. *Clini Exp Rheumatol* 1995;13(3):399-403.
13. Shrikiran A. A rare case of methotrexate induced pancreatitis in acute leukemia patient. *WebmedCentral Paediatrics* 2011;2(12):WMC002820.
14. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. *JOP J Pancreas* 2007;8:S488-S494.
15. Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. *Am J Obstet Gynecol* 1993;168(6):1759-1762.
16. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356(9237):1255-1259.